76 related articles for article (PubMed ID: 28009975)
21. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.
Yao H; Ji M; Zhu Z; Zhou J; Cao R; Chen X; Xu B
Bioorg Med Chem; 2015 Feb; 23(4):681-93. PubMed ID: 25614115
[TBL] [Abstract][Full Text] [Related]
22. Predictive biomarkers for cancer therapy with PARP inhibitors.
Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
[TBL] [Abstract][Full Text] [Related]
23. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
Masutani M; Nakagama H; Sugimura T
Cell Mol Life Sci; 2005 Apr; 62(7-8):769-83. PubMed ID: 15868402
[TBL] [Abstract][Full Text] [Related]
24. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
[TBL] [Abstract][Full Text] [Related]
25. Proteomic investigation of phosphorylation sites in poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase.
Gagné JP; Moreel X; Gagné P; Labelle Y; Droit A; Chevalier-Paré M; Bourassa S; McDonald D; Hendzel MJ; Prigent C; Poirier GG
J Proteome Res; 2009 Feb; 8(2):1014-29. PubMed ID: 19105632
[TBL] [Abstract][Full Text] [Related]
26. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
27. Toward specific functions of poly(ADP-ribose) polymerase-2.
Yélamos J; Schreiber V; Dantzer F
Trends Mol Med; 2008 Apr; 14(4):169-78. PubMed ID: 18353725
[TBL] [Abstract][Full Text] [Related]
28. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair.
Dantzer F; Amé JC; Schreiber V; Nakamura J; Ménissier-de Murcia J; de Murcia G
Methods Enzymol; 2006; 409():493-510. PubMed ID: 16793420
[TBL] [Abstract][Full Text] [Related]
29. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
30. Multiple receptor conformation docking, dock pose clustering and 3D QSAR studies on human poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Fatima S; Jatavath MB; Bathini R; Sivan SK; Manga V
J Recept Signal Transduct Res; 2014 Oct; 34(5):417-30. PubMed ID: 25046176
[TBL] [Abstract][Full Text] [Related]
31. Trapping Poly(ADP-Ribose) Polymerase.
Shen Y; Aoyagi-Scharber M; Wang B
J Pharmacol Exp Ther; 2015 Jun; 353(3):446-57. PubMed ID: 25758918
[TBL] [Abstract][Full Text] [Related]
32. Poly(ADP-ribose) and carcinogenesis.
Masutani M; Nakagama H; Sugimura T
Genes Chromosomes Cancer; 2003 Dec; 38(4):339-48. PubMed ID: 14566854
[TBL] [Abstract][Full Text] [Related]
33. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Horvath EM; Szabó C
Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
[TBL] [Abstract][Full Text] [Related]
34. A scintillation proximity assay for poly(ADP-ribose) polymerase.
Cheung A; Zhang J
Anal Biochem; 2000 Jun; 282(1):24-8. PubMed ID: 10860495
[TBL] [Abstract][Full Text] [Related]
35. Differential contribution of poly(ADP-ribose)polymerase-1 and -2 (PARP-1 and -2) to the poly(ADP-ribosyl)ation reaction in rat primary spermatocytes.
Tramontano F; Malanga M; Quesada P
Mol Hum Reprod; 2007 Nov; 13(11):821-8. PubMed ID: 17766683
[TBL] [Abstract][Full Text] [Related]
36. Pathophysiological role of poly(ADP-ribose) polymerase (PARP) activation during acetaminophen-induced liver cell necrosis in mice.
Cover C; Fickert P; Knight TR; Fuchsbichler A; Farhood A; Trauner M; Jaeschke H
Toxicol Sci; 2005 Mar; 84(1):201-8. PubMed ID: 15601672
[TBL] [Abstract][Full Text] [Related]
37. Development of a miniaturized assay for the high-throughput screening program for poly(ADP-ribose) polymerase-1.
Lee S; Koo HN; Lee BH
Methods Find Exp Clin Pharmacol; 2005 Nov; 27(9):617-22. PubMed ID: 16357945
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel PARP-1 inhibitors by structure-based virtual screening.
Hannigan K; Kulkarni SS; Bdzhola VG; Golub AG; Yarmoluk SM; Talele TT
Bioorg Med Chem Lett; 2013 Nov; 23(21):5790-4. PubMed ID: 24074844
[TBL] [Abstract][Full Text] [Related]
39. PARP-1 interaction with VP1 capsid protein regulates polyomavirus early gene expression.
Carbone M; Reale A; Di Sauro A; Sthandier O; Garcia MI; Maione R; Caiafa P; Amati P
J Mol Biol; 2006 Nov; 363(4):773-85. PubMed ID: 16979186
[TBL] [Abstract][Full Text] [Related]
40. "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors.
Incorvaia L; Passiglia F; Rizzo S; Galvano A; Listì A; Barraco N; Maragliano R; Calò V; Natoli C; Ciaccio M; Bazan V; Russo A
Oncotarget; 2017 Apr; 8(14):23891-23904. PubMed ID: 28055979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]